Strategies for Glycoengineering Therapeutic Proteins

Area of Science:

• Biotechnology
• Pharmaceutical Sciences
• Drug Development

Background:

• Therapeutic proteins are predominantly glycosylated, significantly impacting their safety and pharmacokinetics.
• Glycosylation is increasingly recognized for its role in the pharmacodynamics and therapeutic efficacy of protein-based drugs.

Purpose of the Study:

• To review the established and emerging roles of glycosylation in therapeutic proteins.
• To highlight advancements in glycoengineering for optimizing protein therapeutics.
• To discuss future directions in the deliberate modification of protein glycosylation.

Main Methods:

• Review of existing literature and drug examples.
• Illustrative examples of glycoengineered drugs including cytokines, enzymes, and antibodies.
• Discussion of emerging glycoengineering strategies and enabling technologies.

Main Results:

• Glycoengineering has successfully improved drugs like erythropoietin (EPO) and afucosylated IgG antibodies.
• Examples include Gazyva®, Poteligeo®, Fasenra™, and Uplizna® showcasing glycoengineering benefits.
• Advancements in computational tools, production systems, and metabolic pathway supplementation are key.

Conclusions:

• Deliberate modification of therapeutic protein glycosylation is becoming a more prevalent strategy.
• Glycoengineering offers significant potential for developing next-generation protein therapeutics.
• Continued development in glycoengineering technologies will enhance accessibility and application in drug design.